source
- FDA approves first mRNA seasonal flu vaccine, mFlusiva, a year after funding cutsThe U.S. Food and Drug Administration granted approval to mFlusiva, the first mRNA‑based seasonal influenza vaccine, after its advisory committee voted unanimously that the benefits outweigh the ri…
- Replimune's oncolytic virus therapy Tudriqev receives FDA accelerated approval for advanced melanomaThe U.S. Food and Drug Administration has granted approval to Replimune's melanoma treatment, ending a series of earlier rejections after an advisory panel advocated for the drug. The therapy, pre…